Court stops Teva's launch of Evista copycat; Forest wins patent extension on Namenda;

> Eli Lilly said a U.S. district court granted its request to temporarily stop generic drug maker Teva Pharmaceutical Industries from launching a version of the osteoporosis drug Evista. Report

> The U.S. patent office granted a five-year extension for the Merz Pharma patent covering Forest Laboratories' Alzheimer's remedy Namenda, giving Forest ammo for its patent fight against several generics makers seeking to copy the drug. Release

> As merger mania plays out among the pharmaceutical giants, a different sort of financial frenzy has seized some small, struggling drug makers. Investors are demanding that stragglers close up shop and hand over any remaining cash. Report

> Watson Pharmaceuticals has settled a patent fight with Elan over Watson's generic version of Naprelan (naproxen sodium) tablets. Report

> Scientists have discovered that an old antimalaria drug is effective against two fatal viruses that recently jumped from animals to humans. Report

> Roche and Evotec have signed a potential $300 million deal to develop EVT 101, a drug being tested for treatment-resistant depression. EVT-101 was discovered by Roche and developed by Evotec from discovery to the clinic. Roche report

> Inhalable indulin company MannKind has agreed to purchase Pfizer's Frankfurt-based insulin facility for $33 million. Report

> Human Genome Sciences' experimental hepatitis C drug Albuferon met its primary endpoint of non-inferiority to Pegasys in a Phase III trial. HGS release

> Victory Pharma and Surface Logix have raised $45 million and $20 million respectively. Report

> Japanese drugmaker Takeda Pharmaceuticals saw its shares plunge amid concerns that the company's diabetes drug candidate, alogliptin, faces regulatory delays. Takeda report

> A startup company looking to sell reagents and tools to stem cell researchers hauled in $14 million in Series A cash on the same day the field got a big boost from Uncle Sam. Report

> By many measures, the $3 billion California stem cell agency is a remarkable success. Today the agency is a benchmark for stem cell research and is creating alliances as if it were a nation state, drawing in Australia, Canada, the United Kingdom and Spain. But it now confronts a looming cash crisis as the result of the $42 billion budget shortfall in the Golden State. Article

And Finally... Women using depot medroxyprogesterone acetate (DMPA), a birth control shot sold by Pfizer under the name Depo-Provera, gained an average of 11 pounds and increased their body fat by 3.4 percent over three years. Release

Suggested Articles

Alnylam is ready to follow on its Onpattro launch with an FDA nod for Givlaari. But the drug's safety profile is giving analysts reason to pause.

FDA nominee Stephen Hahn faced questions from Senators on Wednesday on topics including drug pricing, biosimilars, opioids and more.

BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.